Shilpa Medicare Limited (SHILPAMED.NS)
INR 639.9
(4.88%)
INR 639.9
(4.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.56 Billion INR | -44.07% |
| 2022 | 6.34 Billion INR | -16.11% |
| 2021 | 7.55 Billion INR | 20.11% |
| 2020 | 6.29 Billion INR | 1.33% |
| 2019 | 6.21 Billion INR | 39.62% |
| 2018 | 4.44 Billion INR | 13.11% |
| 2017 | 3.93 Billion INR | 9.83% |
| 2016 | 3.58 Billion INR | 32.89% |
| 2015 | 2.69 Billion INR | 4.29% |
| 2014 | 2.58 Billion INR | 10.58% |
| 2013 | 2.33 Billion INR | 49.38% |
| 2012 | 1.56 Billion INR | 16.56% |
| 2011 | 1.34 Billion INR | 15.79% |
| 2010 | 1.15 Billion INR | -0.54% |
| 2009 | 1.16 Billion INR | 78.52% |
| 2008 | 652.74 Million INR | 149.06% |
| 2007 | 262.07 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1 Billion INR | -1.06% |
| 2023 Q1 | 1.72 Billion INR | -1.03% |
| 2023 Q4 | 1.01 Billion INR | -46.55% |
| 2023 Q3 | 1.89 Billion INR | 1.48% |
| 2023 Q2 | 1.87 Billion INR | 8.64% |
| 2023 FY | 3.54 Billion INR | -44.07% |
| 2022 Q3 | 1.56 Billion INR | 7.18% |
| 2022 FY | 6.34 Billion INR | -16.11% |
| 2022 Q1 | 1.57 Billion INR | -28.77% |
| 2022 Q4 | 1.74 Billion INR | 10.91% |
| 2022 Q2 | 1.46 Billion INR | -6.83% |
| 2021 Q1 | 1.61 Billion INR | -3.77% |
| 2021 FY | 7.55 Billion INR | 20.11% |
| 2021 Q4 | 2.2 Billion INR | 22.01% |
| 2021 Q3 | 1.8 Billion INR | -6.28% |
| 2021 Q2 | 1.93 Billion INR | 19.58% |
| 2020 Q4 | 1.67 Billion INR | 31.31% |
| 2020 FY | 6.29 Billion INR | 1.33% |
| 2020 Q2 | 1.75 Billion INR | 10.47% |
| 2020 Q3 | 1.27 Billion INR | -27.13% |
| 2020 Q1 | 1.58 Billion INR | 12.09% |
| 2019 Q3 | 1.73 Billion INR | -12.46% |
| 2019 FY | 6.21 Billion INR | 39.62% |
| 2019 Q1 | 1.07 Billion INR | 15.46% |
| 2019 Q2 | 1.97 Billion INR | 84.47% |
| 2019 Q4 | 1.41 Billion INR | -18.22% |
| 2018 Q3 | 1.07 Billion INR | -8.36% |
| 2018 Q1 | 1.27 Billion INR | 0.35% |
| 2018 FY | 4.44 Billion INR | 13.11% |
| 2018 Q2 | 1.17 Billion INR | -8.26% |
| 2018 Q4 | 928.37 Million INR | -13.49% |
| 2017 FY | 3.93 Billion INR | 9.83% |
| 2017 Q2 | 1.19 Billion INR | 30.52% |
| 2017 Q1 | 915.95 Million INR | -29.25% |
| 2017 Q4 | 1.27 Billion INR | 35.08% |
| 2017 Q3 | 941.67 Million INR | -21.23% |
| 2016 Q1 | 809.38 Million INR | -22.05% |
| 2016 Q4 | 1.29 Billion INR | 35.85% |
| 2016 Q3 | 953.07 Million INR | -6.23% |
| 2016 Q2 | 1.01 Billion INR | 25.58% |
| 2016 FY | 3.58 Billion INR | 32.89% |
| 2015 FY | 2.69 Billion INR | 4.29% |
| 2015 Q1 | 684.75 Million INR | 22.09% |
| 2015 Q2 | 857.36 Million INR | 25.21% |
| 2015 Q3 | 890.74 Million INR | 3.89% |
| 2015 Q4 | 1.03 Billion INR | 16.57% |
| 2014 Q4 | 560.86 Million INR | -23.01% |
| 2014 FY | 2.58 Billion INR | 10.58% |
| 2014 Q1 | 634.83 Million INR | 39.31% |
| 2014 Q2 | 659.85 Million INR | 3.94% |
| 2014 Q3 | 728.47 Million INR | 10.4% |
| 2013 Q2 | 622.45 Million INR | 11.61% |
| 2013 FY | 2.33 Billion INR | 49.38% |
| 2013 Q4 | 455.68 Million INR | -34.99% |
| 2013 Q3 | 700.95 Million INR | 12.61% |
| 2013 Q1 | 557.71 Million INR | 38.22% |
| 2012 Q1 | 399.03 Million INR | 0.34% |
| 2012 Q3 | 400.5 Million INR | 10.85% |
| 2012 Q4 | 403.49 Million INR | 0.74% |
| 2012 Q2 | 361.3 Million INR | -9.46% |
| 2012 FY | 1.56 Billion INR | 16.56% |
| 2011 Q2 | 310.03 Million INR | 1.05% |
| 2011 Q1 | 306.8 Million INR | 0.0% |
| 2011 FY | 1.34 Billion INR | 15.79% |
| 2011 Q4 | 397.69 Million INR | 21.43% |
| 2011 Q3 | 327.51 Million INR | 5.64% |
| 2010 FY | 1.15 Billion INR | -0.54% |
| 2009 FY | 1.16 Billion INR | 78.52% |
| 2008 FY | 652.74 Million INR | 149.06% |
| 2007 FY | 262.07 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 86.7% |
| Hester Biosciences Limited | 1.27 Billion INR | -179.661% |
| Aarti Drugs Limited | 8.31 Billion INR | 57.169% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 38.918% |
| Albert David Limited | 1.4 Billion INR | -152.96% |
| Alembic Limited | 1 Billion INR | -256.152% |
| Alkem Laboratories Limited | 52.29 Billion INR | 93.189% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -687.764% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -142.009% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -28292.961% |
| Brooks Laboratories Limited | 65.62 Million INR | -5328.066% |
| Eris Lifesciences Limited | 10.42 Billion INR | 65.839% |
| FDC Limited | 6.58 Billion INR | 45.919% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 71.351% |
| Gufic Biosciences Limited | 4.07 Billion INR | 12.564% |
| Hikal Limited | 5.95 Billion INR | 40.217% |
| Ind-Swift Limited | 2.17 Billion INR | -63.951% |
| Innova Captab Limited | 3.46 Billion INR | -2.813% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 24.522% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -445.809% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 81.867% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | -88.773% |
| Lupin Limited | 125.09 Billion INR | 97.153% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -415.326% |
| Medico Remedies Limited | 262.14 Million INR | -1258.756% |
| Morepen Laboratories Limited | 6.16 Billion INR | 42.189% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 26.152% |
| Orchid Pharma Limited | 2.32 Billion INR | -53.51% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 38.39% |
| RPG Life Sciences Limited | 2.48 Billion INR | -43.451% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -474.058% |
| Sigachi Industries Limited | 2 Billion INR | -77.892% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 315.103% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 13.615% |
| Themis Medicare Limited | 2.42 Billion INR | -47.185% |
| Unichem Laboratories Limited | 4.86 Billion INR | 26.784% |
| Vaishali Pharma Limited | 90.32 Million INR | -3843.511% |
| Wanbury Limited | 1.73 Billion INR | -105.814% |
| Windlas Biotech Limited | 1.33 Billion INR | -166.051% |
| ZIM Laboratories Limited | 1.26 Billion INR | -180.948% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 13.823% |
| Ipca Laboratories Limited | 48.58 Billion INR | 92.669% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.622% |
| Venus Remedies Limited | 2.18 Billion INR | -63.196% |
| Sakar Healthcare Limited | 699.58 Million INR | -409.144% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 96.748% |
| Divi's Laboratories Limited | 32.44 Billion INR | 89.02% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 42.76% |
| Mankind Pharma Limited | 42.19 Billion INR | 91.559% |
| Sequent Scientific Limited | 2.97 Billion INR | -19.578% |
| Laurus Labs Limited | 15.44 Billion INR | 76.944% |
| Neuland Laboratories Limited | 8.24 Billion INR | 56.814% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 76.657% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 94.863% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.155% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -70.097% |
| Wockhardt Limited | 7.72 Billion INR | 53.861% |
| Bal Pharma Limited | 770.19 Million INR | -362.467% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.823% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 3.614% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -573.153% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 61.311% |
| Valiant Laboratories Limited | 138.02 Million INR | -2480.542% |
| Ajanta Pharma Limited | 21.06 Billion INR | 83.09% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -3051.312% |
| Granules India Limited | 16.79 Billion INR | 78.797% |
| Medicamen Biotech Limited | 495.49 Million INR | -618.856% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -536.618% |
| Piramal Enterprises Limited | 8.04 Billion INR | 55.716% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 92.382% |
| NATCO Pharma Limited | 25.73 Billion INR | 86.16% |
| Suven Life Sciences Limited | -200.79 Million INR | 1873.88% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 3375.398% |
| Strides Pharma Science Limited | 14.38 Billion INR | 75.244% |
| Indoco Remedies Limited | 8.04 Billion INR | 55.714% |
| Alpa Laboratories Limited | 188.89 Million INR | -1785.649% |
| Lasa Supergenerics Limited | 121.02 Million INR | -2842.987% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -810.817% |